Myocardial Infarction incidence during national lockdown in two French provinces unevenly affected by COVID-19 outbreak: An observational study
- PMID: 34173627
- PMCID: PMC7938895
- DOI: 10.1016/j.lanepe.2021.100030
Myocardial Infarction incidence during national lockdown in two French provinces unevenly affected by COVID-19 outbreak: An observational study
Abstract
Background: A reduction of admission for MI has been reported in most countries affected by COVID-19. No clear explanation has been provided.
Methods: To report the incidence of myocardial infarction (MI) admission during COVID-19 pandemic and in particular during national lockdown in two unequally affected French provinces (10-million inhabitants) with a different media strategy, and to describe the magnitude of MI incidence changes relative to the incidence of COVID-19-related deaths. A longitudinal study to collect all MIs from January 1 until May 17, 2020 (study period) and from the identical time period in 2019 (control period) was conducted in all centers with PCI-facilities in northern "Hauts-de-France" province and western "Pays-de-la-Loire" Province. The incidence of COVID-19 fatalities was also collected.
Findings: In "Hauts-de-France", during lockdown (March 18-May 10), 1500 COVID-19-related deaths were observed. A 23% decrease in MI-IR (IRR=0.77;95%CI:0.71-0.84, p<0.001) was observed for a loss of 272 MIs (95%CI:-363,-181), representing 18% of COVID-19-related deaths. In "Pays-de-la-Loire", 382 COVID-19-related deaths were observed. A 19% decrease in MI-IR (IRR=0.81; 95%CI=0.73-0.90, p<0.001) was observed for a loss of 138 MIs (95%CI:-210,-66), representing 36% of COVID-19-related deaths. While in "Hauts-de-France" the MI decline started before lockdown and recovered 3 weeks before its end, in "Pays-de-la-Loire", it started after lockdown and recovered only by its end. In-hospital mortality of MI patients was increased during lockdown in both provinces (5.0% vs 3.4%, p=0.02).
Interpretation: It highlights one of the potential collateral damages of COVID-19 outbreak on cardiovascular health with a dramatic reduction of MI incidence. It advocates for a careful and weighted communication strategy in pandemic crises.
Funding: The study was conducted without external funding.
Keywords: COVID-19 outbreak; COVID-19, Coronavirus disease 2019; Clinical outcome; MI, Myocardial Infarction; Mortality; Myocardial Infarction; NSTEMI, non ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction.
© 2021 The Authors.
Conflict of interest statement
Dr. Lemesle reports personal fees from Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, Lilly, MSD, Mylan, Novartis, Novonordisk, Pfizer, Sanofi Aventis, Servier, outside the submitted work. Dr Delhaye reports personal fees from Medtronic outside the submitted work. Dr. Cayla reports personal fees from Amgen, personal fees from Astra Zeneca, personal fees from Bayer, personal fees from Biotronik, personal fees from Bristol Myers Squibb, grants and personal fees from Medtronic, personal fees from MSD, personal fees from Pfizer, personal fees from Sanofi, outside the submitted work. The other authors do not report any conflict of interest.
Figures
References
-
- Garcia S, Albaghdadi MS, Meraj PM, Schmidt C, Garberich R, Jaffer FA. Reduction in ST-segment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemic. J Am Coll Cardiol. 2020;75(22):2871–2872. doi: 10.1016/j.jacc.2020.04.011. Epub 2020 Apr 10. - DOI - PMC - PubMed
-
- Enache B, Claessens Y-E, Boulay F, Dor V, Eker A, Civaia F. Reduction in cardiovascular emergency admissions in Monaco during the COVID-19 pandemic. Clin Res Cardiol. 2020;109(12):1577–1578. doi: 10.1007/s00392-020-01687. http://link.springer.com/10.1007/s00392-020-01687-w Epub 2020 Jun 12. Available from: - DOI - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous
